Phase I Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine and Rituximab in Previously Treated Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)

Trial Profile

Phase I Study of Obatoclax Mesylate (GX15-070MS) in Combination With Fludarabine and Rituximab in Previously Treated Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Obatoclax (Primary) ; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jul 2013 Planned end date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 17 Jul 2013 Planned end date changed from 1 May 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 29 Jan 2013 Planned number of patients changed from 44 to 28 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top